Buprenorphine treatment has been found to be an effective treatment for opioid use disorder (OUD). Child welfare systems have been partnering with treatment providers to increase access, yet little is known about its role in improving outcomes related to child maltreatment. This paper finds, for the first time, that increased availability of buprenorphine treatment predicts reductions in certain types of child maltreatment caseloads in 25 states. Key findings include:
- Changes in buprenorphine patient capacity have no relationship with the number of children reported to child protective services.
- Increased treatment capacity predicts lower rates of alternative response, in line with expert recommendations that alternative response is not appropriate for parental SUD. Alternative response is an approach to provide supportive services to families with lower-risk maltreatment allegations.
- Increased treatment capacity predicts lower rates of substantiated abuse or neglect, suggesting treatment is effective in reducing immediate risk to children.
- However, children with unsubstantiated maltreatment are still at risk if supportive services are not provided.
- Substance use, the Opioid Epidemic and the Child Welfare System: Key Findings from a Mixed Methods Study
- Medication-Assisted Treatment for Opioid Use Disorder in the Child Welfare Context: Challenges and Opportunities
- Challenges in Providing Substance Use Disorder Treatment to Child Welfare Clients in Rural Communities
- Availability of Treatment for Opioid Use Disorder in Areas of High Foster Care Increases
- Strategies Rural Communities Use to Address Substance Misuse among Families in the Child Welfare System
- Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Robin Ghertner, (202) 765-6954 , email@example.com. Content will be updated pending the outcome of the Section 508 review.